Comparative Pharmacology
Head-to-head clinical analysis: BUTALAN versus NEMBUTAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALAN versus NEMBUTAL SODIUM.
BUTALAN vs NEMBUTAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing neuronal inhibition. Depresses the reticular activating system at higher doses.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
30 mg IV or IM every 6 to 8 hours as needed for sedation; 65 to 100 mg IV or IM for hypnosis; 200 to 500 mg IV or IM for anticonvulsant effect in status epilepticus. Maximum single dose 500 mg.
None Documented
None Documented
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 15-40 hours in adults; clinically relevant for accumulation with repeated dosing, especially in hepatic impairment.
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Renal: ~25% unchanged; hepatic metabolism to inactive metabolites; ~50% excreted as metabolites in urine; biliary/fecal: minor.
Category C
Category C
Barbiturate
Barbiturate